Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 16;12(1):4567.
doi: 10.1038/s41598-022-08507-3.

Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases

Affiliations

Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases

Rupesh Kotecha et al. Sci Rep. .

Abstract

The unique acute effects of the large fractional doses that characterize stereotactic radiosurgery (SRS) or radiotherapy (SRT), specifically in terms of antitumor immune cellular processes, vascular damage, tumor necrosis, and apoptosis on brain metastasis have yet to be empirically demonstrated. The objective of this study is to provide the first in-human evaluation of the acute biological effects of SRS/SRT in resected brain metastasis. Tumor samples from patients who underwent dose-escalated preoperative SRT followed by resection with available non-irradiated primary tumor tissues were retrieved from our institutional biorepository. All primary tumors and irradiated metastases were evaluated for the following parameters: tumor necrosis, T-cells, natural killer cells, vessel density, vascular endothelial growth factor, and apoptotic factors. Twenty-two patients with irradiated and resected brain metastases and paired non-irradiated primary tumor samples met inclusion criteria. Patients underwent a median preoperative SRT dose of 18 Gy (Range: 15-20 Gy) in 1 fraction, with 3 patients receiving 27-30 Gy in 3-5 fractions, followed by resection within median interval of 67.8 h (R: 18.25-160.61 h). The rate of necrosis was significantly higher in irradiated brain metastases than non-irradiated primary tumors (p < 0.001). Decreases in all immunomodulatory cell populations were found in irradiated metastases compared to primary tumors: CD3 + (p = 0.003), CD4 + (p = 0.01), and CD8 + (p = 0.01). Pre-operative SRT is associated with acute effects such as increased tumor necrosis and differences in expression of immunomodulatory factors, an effect that does not appear to be time dependent, within the limited intervals explored within the context of this analysis.

PubMed Disclaimer

Conflict of interest statement

R. Kotecha: Honoraria from Accuray Inc., Elekta AB, Viewray Inc., Novocure Inc., Elsevier Inc., Brainlab. Institutional research funding from Medtronic Inc., Blue Earth Diagnostics Ltd., Novocure Inc., GT Medical Technologies, Astrazeneca, Exelixis, Viewray Inc., Brainlab. R. Tonse: None. M. Menendez: None. A. Williams: None. Z. Diaz: None. M. Tom: Honoraria from Viewray Inc. Institutional research funding from Blue Earth Diagnostics Ltd. M. Hall: Honorarium from Accuray, Inc. Proton Collaborative Group Executive Committee Institutional Representative and Voting Member, Miami Cancer Institute (unpaid). Grant Funding: Live Like Bella Pediatric Cancer Research Initiative, Florida Department of Health Grant 8LA04. M.P. Mehta: Consulting for Karyopharm, Sapience, Xoft, Zap, Mevion. Board of Directors: Oncoceutics; Stock: Chimerix. R. Alvarez: None. V. Siomin: None. M. S. Ahluwalia: Receipt of grants/research supports: Astrazeneca, BMS, Bayer, Incyte, Pharmacyclics, Novocure, Mimivax, Merck. Receipt of honoraria or consultation fees: Bayer, Novocure, Kiyatec, Insightec, GSK, Xoft, Nuvation, Cellularity, SDP Oncology, Apollomics, Prelude, Janssen. Stock shareholder: Doctible, Mimivax, Cytodyn, MedInnovate Advisors LLC. Y.Odia: Institutional research funding: BMS, Novocure Inc., DSMC: GammaTile, Actuate, Oncoceutics/Chimerix. Advisory Board: Novocure Inc, Abbvie. Consulting: Abbvie. M. W. McDermott: Consulting for Deinde Medical and Stryker Corporation.

Figures

Figure 1
Figure 1
Representative tissue samples displaying the acute effects of stereotactic radiosurgery in brain metastasis. Hematoxylin and eosin staining showing necrosis of a primary tumor (NSCLC) sample (A); primary tissue sections were immunohistochemically stained for CD3 + (B), CD4 + (C), and CD8 + (D) cells. Hematoxylin and eosin staining demonstrated an increase in necrosis in the paired resected brain metastasis after pre-operative SRS (E). Additionally, a decrease in all immunomodulatory cell populations, including CD3 + (F), CD4 + (G), and CD8 + cells (H) were observed on pairwise comparison. (Original magnification × 40).
Figure 2
Figure 2
Relationship for the percentage of tumor necrosis between the primary tumor and irradiated BM: (A) tumor necrosis in primary tumors was significantly lower than irradiated BM; (B) no difference in the proportion of tumor necrosis with respect to time interval from SRT to surgery was observed: primary (non-irradiated), BM < 24 h, 24–48 h, 48–72 h and > 72 h.
Figure 3
Figure 3
Paired box plots representing the immunomodulatory effects of pre-operative stereotactic radiotherapy on metastasis tumors compared to non-irradiated primary tumors on immunomodulatory cells, including CD3 + (T-cell receptor) (A), CD4 + (T helper cell) (B), and CD8 + (cytotoxic T lymphocytes) (C).

Similar articles

Cited by

References

    1. Suh JH, et al. Current approaches to the management of brain metastases. Nat. Rev. Clin. Oncol. 2020;17:279–299. doi: 10.1038/s41571-019-0320-3. - DOI - PubMed
    1. Giordana MT, Cordera S, Boghi A. Cerebral metastases as first symptom of cancer: A clinico-pathologic study. J. Neurooncol. 2000;50:265–273. doi: 10.1023/a:1006413001375. - DOI - PubMed
    1. Patchell RA, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 1990;322:494–500. doi: 10.1056/NEJM199002223220802. - DOI - PubMed
    1. Prabhu RS, et al. Single-fraction stereotactic radiosurgery (SRS) alone versus surgical resection and SRS for large brain metastases: A multi-institutional analysis. Int. J. Radiat. Oncol. Biol. Phys. 2017;99:459–467. doi: 10.1016/j.ijrobp.2017.04.006. - DOI - PubMed
    1. Patchell RA, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 1998;280:1485–1489. doi: 10.1001/jama.280.17.1485. - DOI - PubMed

Publication types

Substances